Amicus Therapeutics spins off genetic medicine unit in $600M SPAC deal

Amicus Therapeutics Inc., a life sciences company which at the start of this year moved it headquarters from New Jersey to Philadelphia, unveiled plans Wednesday to spinoff a "next-generation genetic medicine company" in a deal valued at $600 million. The company, Caritas Therapeutics, is being created through a merger of part of the gene therapy business of Amicus (NASDAQ: FOLD) with ARYA Sciences Acquisition Corp. IV, a special purpose acquisition company, or SPAC, sponsored by Perceptive Advisors.…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news